Cohance Lifesciences posts ₹24.1 crore loss in Q1 FY27 as revenue falls 23%
Synopsis
Cohance Lifesciences went from a ₹48.9 crore profit to a ₹24.1 crore loss in just one year — and the real shock is the EBITDA, which cratered 99% to barely ₹1.2 crore. For a CDMO platform that serves innovators in over 60 countries, a margin collapse from 20.4% to 0.3% in a single quarter demands explanation. Investors, so far, are holding their nerve.
Key Takeaways
Cohance Lifesciences posted a net loss of ₹24.1 crore in Q1 FY27 , reversing a profit of ₹48.9 crore in Q1 FY26.
Revenue from operations fell 23.1% year-on-year to ₹422 crore , from ₹549 crore a year ago.
EBITDA collapsed 99% to ₹1.2 crore ; EBITDA margin shrank from 20.4% to 0.3% .
The stock closed at ₹428.40 on the BSE , up 0.82% on the day despite the weak results.
Over six months, the stock is still up 20.07% , reflecting longer-term investor confidence in the CDMO sector.
The company serves pharmaceutical innovators in more than 60 countries and was formed via merger with Suven Pharmaceuticals .
Cohance Lifesciences Limited swung to a consolidated net loss of ₹24.1 crore in Q1 FY27 (April–June 2025), a sharp reversal from the ₹48.9 crore net profit it posted in the same quarter a year earlier. The Hyderabad-headquartered pharma CDMO and API platform disclosed the results through a stock exchange filing on Wednesday, 5 August.
Revenue and Operating Performance
Revenue from operations declined 23.1% year-on-year to ₹422 crore in the June quarter, down from ₹549 crore in Q1 FY26. The contraction reflects a broad-based softness across the company's business lines, though the company has not yet detailed which geographies or product segments drove the steepest declines.
The operating performance deteriorated even more steeply. EBITDA plunged 99% to just ₹1.2 crore from ₹112 crore in the year-ago period. Consequently, the EBITDA margin collapsed to 0.3% from 20.4% — a contraction of more than 20 percentage points in a single year.
Stock Market Reaction
Despite the weak quarterly numbers, the company's shares closed marginally higher on the Bombay Stock Exchange (BSE), ending at ₹428.40, up ₹3.50 or 0.82% on the day. Markets may have already priced in the disappointment, or investors could be looking past the near-term pain toward the company's longer-term pipeline.
Over the past five days, the stock has been broadly flat, rising just 0.34%. It has shed 5.42% over the last month but remains up 20.07% over the past six months, reflecting underlying investor confidence in the CDMO sector's structural growth story even as quarterly numbers disappoint.
About Cohance Lifesciences
Cohance Lifesciences was formed following a series of corporate restructuring steps, including its merger with Suven Pharmaceuticals. The company operates as a technology-driven global Contract Development and Manufacturing Organization (CDMO) and active pharmaceutical ingredient (API) platform, offering end-to-end lifecycle solutions across small molecules, antibody-drug conjugates (ADCs), and oligonucleotides.
Its business spans pharma CDMO services, high-value complex APIs under its API+ platform, and specialty chemicals. The company serves global pharmaceutical innovators across more than 60 countries through multiple manufacturing facilities and specialised research and development centres, with particular expertise in ADC payloads and oligonucleotide building blocks.
What to Watch
The near-total erosion of operating margins in a single quarter raises questions about cost structures and revenue visibility for the remainder of FY27. Analysts and investors will closely track management commentary on order book recovery, client pipeline, and whether the margin compression is temporary — linked to project timing — or indicative of structural pricing pressure in the global CDMO market.
Point of View
Areas where global demand is rising, but a single quarter that wipes out nearly all operating profit raises urgent questions about revenue concentration and project timing risk. The stock's muted reaction suggests markets are treating this as a one-off, but that assumption needs validation from management. If the margin compression persists into Q2, the six-month gain of 20% will look increasingly fragile.
NationPress
6 Aug 2026
Frequently Asked Questions
What were Cohance Lifesciences' Q1 FY27 financial results?
Cohance Lifesciences reported a consolidated net loss of ₹24.1 crore in Q1 FY27, compared to a net profit of ₹48.9 crore in Q1 FY26. Revenue fell 23.1% to ₹422 crore and EBITDA crashed 99% to ₹1.2 crore.
Why did Cohance Lifesciences' EBITDA fall so sharply?
The company's EBITDA plunged 99% year-on-year to ₹1.2 crore from ₹112 crore, with the EBITDA margin contracting from 20.4% to 0.3%. The company has not yet publicly detailed the specific drivers, though the steep revenue decline of 23.1% is a key factor.
How did Cohance Lifesciences shares react to the Q1 results?
Despite the significant loss, Cohance Lifesciences shares ended the day marginally higher at ₹428.40 on the BSE, up 0.82%. The stock has declined 5.42% over the past month but remains up 20.07% over six months.
What does Cohance Lifesciences do?
Cohance Lifesciences is a Hyderabad-based global CDMO and API platform that provides end-to-end drug development and manufacturing services across small molecules, antibody-drug conjugates (ADCs), and oligonucleotides. It serves pharmaceutical innovators in over 60 countries and was formed through a merger with Suven Pharmaceuticals.
What should investors watch for in the coming quarters?
Investors will focus on management commentary around order book recovery, client pipeline strength, and whether the near-total margin compression in Q1 FY27 is a temporary project-timing issue or reflects deeper pricing pressure in the global CDMO market.
